About   Help   FAQ
Phenotypes associated with this allele
Allele Symbol
Allele Name
Allele ID 		Mapkapk2tm1.1Yaff
targeted mutation 1.1, Michael Yaffe
MGI:5528531
Summary 3 genotypes
Jump to Allelic Composition Genetic Background Genotype ID
hm1
 		Mapkapk2tm1.1Yaff/Mapkapk2tm1.1Yaff involves: 129S4/SvJae * C57BL/6 MGI:5528650
cn2
 		Krastm4Tyj/Kras+
Mapkapk2tm1.1Yaff/Mapkapk2tm1.1Yaff
Trp53tm1Brn/Trp53tm1Brn 		involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 MGI:5528686
cn3
 		Krastm4Tyj/Kras+
Mapkapk2tm1.1Yaff/Mapkapk2tm1.1Yaff 		involves: 129S4/SvJae * C57BL/6 MGI:5528687


Genotype
MGI:5528650
hm1
Allelic
Composition		 Mapkapk2tm1.1Yaff/Mapkapk2tm1.1Yaff
Genetic
Background		 involves: 129S4/SvJae * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Mapkapk2tm1.1Yaff mutation (1 available); any Mapkapk2 mutation (35 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
normal phenotype
no abnormal phenotype detected ( J:203686 )
• homozygotes are viable and fertile




Genotype
MGI:5528686
cn2
Allelic
Composition		 Krastm4Tyj/Kras+
Mapkapk2tm1.1Yaff/Mapkapk2tm1.1Yaff
Trp53tm1Brn/Trp53tm1Brn
Genetic
Background		 involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Krastm4Tyj mutation (9 available); any Kras mutation (84 available)
Mapkapk2tm1.1Yaff mutation (1 available); any Mapkapk2 mutation (35 available)
Trp53tm1Brn mutation (18 available); any Trp53 mutation (240 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
neoplasm
increased lung adenoma incidence ( J:203686 )
• lung adenocarcinomas cover 11% of lung area 6 weeks after administration of a Cre-recombinase expressing adenovirus
• tumor burden progresses from 11% of lung (6 weeks) to 45% at experimental endpoint (12+ weeks) in the presence of a Cre-recombinase expressing adenovirus
• Mapkap2 expressing tumors (MK2+) represent a higher proportion of tumor burden, however over time the proportion of these tumors decreases and the proportion of Mapkapk2 (MK2-) null tumors increases in the presence of a Cre-recombinase expressing adenovirus
• proportion of total lung tumor burden composed of Mapkapk2 (MK2-) null tumors is reduced from 39% to 11% following cisplatin treatment

respiratory system
increased lung adenoma incidence ( J:203686 )
• lung adenocarcinomas cover 11% of lung area 6 weeks after administration of a Cre-recombinase expressing adenovirus
• tumor burden progresses from 11% of lung (6 weeks) to 45% at experimental endpoint (12+ weeks) in the presence of a Cre-recombinase expressing adenovirus
• Mapkap2 expressing tumors (MK2+) represent a higher proportion of tumor burden, however over time the proportion of these tumors decreases and the proportion of Mapkapk2 (MK2-) null tumors increases in the presence of a Cre-recombinase expressing adenovirus
• proportion of total lung tumor burden composed of Mapkapk2 (MK2-) null tumors is reduced from 39% to 11% following cisplatin treatment




Genotype
MGI:5528687
cn3
Allelic
Composition		 Krastm4Tyj/Kras+
Mapkapk2tm1.1Yaff/Mapkapk2tm1.1Yaff
Genetic
Background		 involves: 129S4/SvJae * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Krastm4Tyj mutation (9 available); any Kras mutation (84 available)
Mapkapk2tm1.1Yaff mutation (1 available); any Mapkapk2 mutation (35 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
neoplasm
increased lung adenoma incidence ( J:203686 )
• lung adenocarcinomas cover 9% of lung area 9 weeks after administration of a Cre-recombinase expressing adenovirus
• tumor burden progresses from 9% of lung (6 weeks) to 28% at experimental endpoint (12+ weeks) in the presence of a Cre-recombinase expressing adenovirus
• Mapkap2 expressing tumors (MK2+) represent a higher proportion of tumor burden in relation to Mapkapk2 (MK2-) null tumors in the presence of a Cre-recombinase expressing adenovirus adenovirus

respiratory system
increased lung adenoma incidence ( J:203686 )
• lung adenocarcinomas cover 9% of lung area 9 weeks after administration of a Cre-recombinase expressing adenovirus
• tumor burden progresses from 9% of lung (6 weeks) to 28% at experimental endpoint (12+ weeks) in the presence of a Cre-recombinase expressing adenovirus
• Mapkap2 expressing tumors (MK2+) represent a higher proportion of tumor burden in relation to Mapkapk2 (MK2-) null tumors in the presence of a Cre-recombinase expressing adenovirus adenovirus




Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources
Funding Information
Warranty Disclaimer, Privacy Notice, Licensing, & Copyright
Send questions and comments to User Support. 		last database update
11/19/2024
MGI 6.24 		The Jackson Laboratory